ABOUT SIK

In October 2007, the FDA announced which the labeling for all PDE5 inhibitors, such as tadalafil, demands a additional notable warning of the possible threat of sudden hearing decline as the results of put up-promoting studies of short-term deafness associated with utilization of PDE5 inhibitors.[19]Diagnosticiranje in reševanje problemov v razli�